Sep 26 |
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
|
Sep 25 |
Centessa Pharmaceuticals: Progressing SerpinPC Through Registrational Trials In Hemophilia B
|
Sep 20 |
Centessa Pharmaceuticals rises after upgrade to Overweight at Morgan Stanley
|
Sep 19 |
Centessa Pharmaceuticals a new buy at B Riley on sleep disorders pipeline
|
Sep 13 |
Centessa Pharmaceuticals prices $225M equity offfering
|
Sep 13 |
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
|
Sep 11 |
Centessa Pharmaceuticals announces $150M proposed public offering of American Depositary Shares
|
Sep 11 |
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
|
Sep 10 |
Top Midday Gainers
|
Sep 10 |
Sleep-Disorder Focused Centessa Pharmaceuticals Unveils Interim Data From Lead Program In Acutely Sleep-Deprived Healthy Volunteers
|